Latest Glycogen storage disease type II Stories
The HCMA Says a Simple Genetic Test Can Tell For Sure HIBERNIA, N.J., Feb. 1 /PRNewswire-USNewswire/ -- Hypertrophic Cardiomyopathy (HCM) is a genetic disease that causes the heart muscle to become abnormally large.
As scientists work to find new treatments for Pompe disease -- the devastating genetic "villain" that drives the efforts of the main characters in the new film "Extraordinary Measures" -- University of Florida researchers are hopeful that gene therapy will help patients in the late stages of the disease breathe on their own.
CRANBURY, N.J., Jan. 11 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today outlined the Company's three key strategic priorities and presented a corporate outlook for 2010 at the 28th Annual J.P. Morgan Healthcare Conference.
CRANBURY, N.J., Sept. 30 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced it plans to initiate a Phase 1 study of AT2220 (1-deoxynojirimycin HCl), its investigational drug in development for the treatment of Pompe Disease.
Brain may win out over brawn as the primary cause of breathing problems in children with a severe form of muscular dystrophy known as Pompe disease.
CRANBURY, N.J., Feb.
CRANBURY, N.J., Feb. 18 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) announced today that Stephen Bloch, M.D., General Partner with Canaan Equity Partners, has resigned from the Company's Board of Directors effective February 17, 2009. Dr.
CRANBURY, N.J., Jan. 29 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) will announce fourth quarter and full year 2008 financial results after the regular close of markets on Thursday, February 5, 2009.
Company Expects to Deliver Multiple Clinical Milestones throughout the Year; Amigal to Initiate Phase 3 Global Development in Second Quarter; Continued Strong Financial Position CRANBURY, N.J., Jan.
- The governor of a province or people.